Improved therapeutic index of an acidic pH-selective antibody

Although therapeutically efficacious, ipilimumab can exhibit dose-limiting toxicity that prevents maximal efficacious clinical outcomes and can lead to discontinuation of treatment. We hypothesized that an acidic pH-selective ipilimumab (pH Ipi), which preferentially and reversibly targets the acidi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Peter S., MacDonald, Katherine G., Massi, Evan, Chew, Pamela V., Bee, Christine, Perkins, Padma, Chau, Bryant, Thudium, Kent, Lohre, Jack, Nandi, Pradyot, Deyanova, Ekaterina G., Barman, Ishita, Gudmundsson, Olafur, Dollinger, Gavin, Sproul, Tim, Engelhardt, John J., Strop, Pavel, Rajpal, Arvind
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865267/
https://www.ncbi.nlm.nih.gov/pubmed/35192429
http://dx.doi.org/10.1080/19420862.2021.2024642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865267/
https://www.ncbi.nlm.nih.gov/pubmed/35192429
http://dx.doi.org/10.1080/19420862.2021.2024642

Ejemplares similares